

Diabetes mellitus Typ 2

Medikamentöse Therapie

L. Cornelius Bollheimer, Christiane Girlich, Ulrike Woenckhaus und Roland Büttner, Regensburg

Arzneimitteltherapie 2007;25:175–86.

Literatur

1. Deutsche Diabetes Gesellschaft. Evidenzbasierte Leitlinie: Epidemiologie und Verlauf des Diabetes mellitus in Deutschland. http://www.deutsche-diabetes-gesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Update_Epidemiologie_05_2004_neues_Layout.pdf. Internetdokument. 2004.
2. Seufert J. Kardiovaskuläre Endpunktstudien in der Therapie des Typ-2-Diabetes-mellitus. Dtsch Arztebl 2006;103:A934–42.
3. Deutsche Diabetes Gesellschaft. Praxis-Leitlinien der Deutschen Diabetes Gesellschaft. Diabetologie und Stoffwechsel 2006;1:S2.
4. Häring HU, Matthaer S. Behandlung des Diabetes mellitus Typ 2. Diabetologie und Stoffwechsel 2006;1:S205–10.
5. Brueckel J, Kerner W. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie und Stoffwechsel 2006;1:S177–80.
6. Leiter LA, Ceriello A, Davidson JA, Hanefeld M, et al. Postprandial glucose regulation: New data and new implications. Clin Ther 2005;27(Suppl B):S42–56.
7. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881–5.
8. Bastyr EJ, III, Stuart CA, Brodows RG, Schwartz S, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000;23:1236–41.
9. AWMF, AkdÄ, ÄZQ, BÄK, DDG, DGIM. Nationale Versorgungs-Leitlinie Diabetes mellitus Typ 2 <http://www.leitlinien.de/versorgungsleitlinien/diabetes2/nvldiabetesmellitustyp2lang/view>. Internetdokument. 2002.
10. Ärztliche Zentralstelle für Qualitätssicherung (ÄZQ). Nationale Versorgungs-Leitlinie Diabetes mellitus Typ 2, Kurzfassung. Internist 2002;43:M164–78.
11. American College of Endocrinology (ACE). Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002;8:S5–11.
12. International Diabetes Federation (IDF). Global Guideline for Type 2 diabetes – Section 06: Glucose Control Levels. <http://www.idf.org/webdata/docs/GGT2D%2006%20Glucose%20control%20levels.pdf>. Internetdokument. 2005.
13. American Diabetes Association. Standards of medical care in diabetes – 2006. Diabetes Care 2006;29:S4–42.
14. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–28.
15. Hauner H. Evidenzbasierte Therapie der Adipositas. Internist 2006;47:159–70.
16. Kulkarni K. Diets do not fail: the success of medical nutrition therapy in patients with diabetes. Endocr Pract 2006;12:S121–3.
17. Witters LA. The blooming of the French lilac. J Clin Invest 2001;108:1105–7.
18. Zhou G, Myers R, Li Y, Chen Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–74.
19. DeFronzo RA. Pathogenesis of type 2 diabetes: Implications for metformin. Drugs 1999;58:S29–30.
20. Lebovitz HE. Oral antidiabetic agents: 2004. Med Clin North Am 2004;88:847–63.
21. U.K. Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83–8.
22. Grant PJ, Stickland MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991;8:361–5.
23. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16:621–9.
24. Akbar DH. Effect of metformin and sulphonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine 2003;20:215–8.
25. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385–411.
26. Parhofer KG, Laubach E, Geiss HC, Otto C. Effect of glucose control on lipid levels in patients with type 2 diabetes. Dtsch Med Wochenschr 2002;127:958–62.
27. DeFronzo RA, Barzilay N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294–301.
28. Cryer DR, Nicholas SP, Henry DH, Mills DJ, et al. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005;28:539–43.
29. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594–2602.
30. Holstein A, Egberts EH. Traditionelle Metformin-Kontraindikationen – mehr Schaden als Nutzen? Dtsch Med Wochenschr 2006;131:105–10.
31. Myers GL, Miller WG, Coresh J, Fleming J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006;52:5–18.
32. Pladevall M, Williams LK, Potts LA, Divine G, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800–5.
33. Holman RR. Long-term efficacy of sulphonylureas: A United Kingdom prospective diabetes study perspective. Metabolism 2006;55:S2–5.
34. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001;27:305–13.
35. Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoeconom Drug Saf 2001;10:537–47.
36. Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003;7:369–79.
37. Isley WL. Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2003;2:581–6.
38. Semple RK, Chatterjee VK, O’Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006;116:581–9.
39. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005;288:H1037–43.
40. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280–8.
41. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605–11.
42. Scherbaum WA, Göke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002;34:589–95.

Priv.-Doz. Dr. med. Cornelius Bollheimer, Klinik und Poliklinik für Innere Medizin I (Direktor: Prof. Dr. J. Schölmerich), Universität Regensburg, 93042 Regensburg, E-Mail: cornelius.bollheimer@klinik.uni-regensburg.de

Dr. med. Christiane Girlich, Dr. med. Ulrike Woenckhaus, Priv.-Doz. Dr. med. Roland Büttner, Klinik und Poliklinik für Innere Medizin I, Universität Regensburg, 93042 Regensburg

43. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. *JAMA* 2000;283:1695–1702.
44. Vongthavaravat V, Wajchenberg BL, Waitman JN, Quimpo JA, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. *Curr Med Res Opin* 2002;18:456–61.
45. Raskin P, Rendell M, Riddle MC, Dole JF, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. *Diabetes Care* 2001;24:1226–32.
46. Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. *Diabetes Obes Metab* 2005;7:633–41.
47. Scheen AJ. Combined thiazolidinedione-insulin therapy: Should we be concerned about safety? *Drug Saf* 2004;27:841–56.
48. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2003;11:405–14.
49. Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. *Diabetes Obes Metab* 2006;8:110–5.
50. Kahn SE, Haffner SM, Heise MA, Herman WH, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 2006;355:2427–43.
51. Yki-Jarvinen H. Thiazolidinediones. *N Engl J Med* 2004;351:1106–18.
52. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. *Lancet* 2005;366:1279–89.
53. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. *Diabetologia* 2005;48:1726–35.
54. Kendall DM. Thiazolidinediones: the case for early use. *Diabetes Care* 2006;29:154–7.
55. Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. *Ann Pharmacother* 2004;38:1419–23.
56. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. *Diabetes Care* 2002;25:815–21.
57. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. *Ann Intern Med* 2001;135:306.
58. Al Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. *Ann Intern Med* 2000;132:121–4.
59. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. *Ann Intern Med* 2000;132:118–21.
60. Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. *Expert Opin Investig Drugs* 2006;15:243–50.
61. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. *Diabetes Technol Ther* 2004;6:850–63.
62. Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. *World J Gastroenterol* 2006;12:2161–7.
63. Bryan J, Crane A, Vila-Carriles WH, Babenko AP, et al. Insulin secretagogues, sulphonylurea receptors and K(ATP) channels. *Curr Pharm Des* 2005;11:2699–2716.
64. Proks P, Reimann F, Green N, Gribble F, et al. Sulphonylurea stimulation of insulin secretion. *Diabetes* 2002;51:S368–76.
65. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. *Drugs* 2004;64:1339–58.
66. Del Prato S, Pulizzi N. The place of sulphonylureas in the therapy for type 2 diabetes mellitus. *Metabolism* 2006;55:S20–7.
67. Stephan D, Winkler M, Kuhner P, Russ U, et al. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels. *Diabetologia* 2006;49:2039–48.
68. Dornhorst A. Insulinotropic meglitinide analogues. *Lancet* 2001;358:1709–16.
69. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837–53.
70. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulphonylureas and metformin. *Diabetologia* 2006;49:930–6.
71. Bell DS. Do sulphonylurea drugs increase the risk of cardiac events? *CMAJ* 2006;174:185–6.
72. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, et al. Dose-response relation between sulphonylurea drugs and mortality in type 2 diabetes mellitus: A population-based cohort study. *CMAJ* 2006;174:169–74.
73. Stevens RJ, Coleman RL, Adler AI, Stratton IM, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. *Diabetes Care* 2004;27:201–7.
74. Chiasson JL, Josse RG, Gomis R, Hanefeld M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. *JAMA* 2003;290:486–94.
75. Chiasson JL, Josse RG, Gomis R, Hanefeld M, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 2002;359:2072–7.
76. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. *Diabetes Care* 2005;28:154–63.
77. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. *Diabetologia* 2004;47:357–66.
78. Iltz JL, Baker DE, Setter SM, Keith CR. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. *Clin Ther* 2006;28:652–65.
79. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. *Diabetes Care* 2005;28:1936–40.
80. Kendall DM, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. *Diabetes Technol Ther* 2006;8:385–96.
81. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest* 1999;104:787–94.
82. Maggs DG, Fineman M, Kornstein J, Burrell T, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. *Diabetes Metab Res Rev* 2004;20:55–60.
83. Hollander P, Maggs DG, Ruggles JA, Fineman M, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. *Obes Res* 2004;12:661–8.
84. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. *JAMA* 2005;294:2581–6.
85. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. *Diabetes* 1995;44:1249–58.
86. Wright A, Burden AC, Paisey RB, Cull CA, et al. Sulphonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). *Diabetes Care* 2002;25:330–6.
87. Pfeiffer EF, Schöffling K, Steigerwald H, Treser G, et al. Das Problem des Sekundärversagens der oralen Diabetesbehandlung. *Dtsch Med Wochenschr* 1957;82:1528–31.
88. Hagen H, Heinsen HA. Kritisches zur peroralen Diabetestherapie. *Med Klin* 1956;51:1217–21.
89. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. *Diabetes Educ* 2006;32:S9–18.
90. Scholze A. Angst vor Insulin-Therapie bei Typ-2-Diabetikern. Fakultät für Pädagogik, Philosophie und Psychologie der Otto-Friedrich-Universität Bamberg. Inauguraldissertation 2005.
91. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. *Diabetes Care* 2005;28:2543–5.
92. Kulzer B. Motivationsprobleme von Typ-2-Diabetikern: Schulung muss im Alltag ankommen. *Pflege Z* 2001;54:637–40.
93. Schiel R, Voigt U, Ross IS, Braun A, et al. Structured diabetes therapy and education improves the outcome of patients with insulin treated diabetes mellitus. The 10 year follow-up of a prospective, population-based survey on the quality of diabetes care (the JEVIN Trial). *Exp Clin Endocrinol Diabetes* 2006;114:18–27.
94. Riddle MC. Making the transition from oral to insulin therapy. *Am J Med* 2005;118:S14–20.
95. Davis T, Edelman SV. Insulin therapy in type 2 diabetes. *Med Clin North Am* 2004;88:865–95.
96. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. *Diabetes Care* 2001;24:758–67.
97. Pugh JA, Wagner ML, Sawyer J, Ramirez G, et al. Is combination sulphonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. *Diabetes Care* 1992;15:953–9.
98. Peters AL, Davidson MB. Insulin plus a sulphonylurea agent for treating type 2 diabetes. *Ann Intern Med* 1991;115:45–53.
99. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 2003;26:3080–6.

100. Yki-Jarvinen H, Dressler A, Ziemens M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. *Diabetes Care* 2000;23:1130–6.
101. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. *Diabetes Care* 2005;28:254–9.
102. Hermansen K, Dereziński T, Kim H, Gall MA. Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycemia and less weight gain than NPH insulin at comparable level of glycaemic improvement in people with type 2 diabetes. *Diabetologia*. EASD 2004: Abstract 754.
103. Menz W. Insuline – AABG:Preisgünstige Therapiealternativen nach § 115c SGB V. *Arzneimitteltherapie* 2006;24:187–96.
104. Garber AJ, Wahlen J, Wahl T, Bressler P, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes Obes Metab* 2006;8:58–66.
105. Malone JK, Kerr LF, Campaigne BN, Sachson RA, et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. *Clin Ther* 2004;26:2034–44.
106. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. *Drugs* 2006;66:31–49.
107. Halimi S, Raskin P, Liebl A, Kawamori R, et al. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. *Clin Ther* 2005;27(Suppl 2):S57–74.
108. Raskin P, Allen E, Hollander P, Lewin A, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care* 2005;28:260–5.
109. Roach P, Trautmann M, Arora V, Sun B, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. *Clin Ther* 1999;21:523–34.
110. Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. *Eur J Intern Med* 2004;15:496–502.
111. Boehm BO, Home PD, Behrend C, Kamp NM, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. *Diabet Med* 2002;19:393–9.
112. Roach P, Yue L, Arora V. Improved postprandial glycaemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. *Diabetes Care* 1999;22:1258–61.
113. Lundershausen R, Potthoff F, Kaiser M, Häuser Ch, et al. Supplementäre Insulin-Therapie bei Patienten mit Typ-2-Diabetes – die PHAZIT-Studie. *Diabetologie und Stoffwechsel* 2006;1:54–9.
114. Kalfhaus J, Berger M. Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study. *Diabetes Metab* 2000;26:197–201.
115. Kazda C, Hulstrunk H, Helsberg K, Langer F, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. *J Diabetes Complications* 2006;20:145–52.
116. IQWiG. Bewertung des therapeutischen Nutzens von inhalativem Insulin im Rahmen der Behandlung des Diabetes mellitus. <http://www.iqwig.de>. Internetdokument 2006.
117. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. *Diabetes Care* 2006;29:1818–25.
- 117a. Bruns W, Worms F, Altmann B. Therapie des Insulinmangels. In: Bruns W, Fiedler H (Hrsg.). *Insulin-Therapie des Typ 2 Diabetes*. Bremen-London-Boston: UNI-MED Verlag AG, 2004:55–72.
118. Büttner R, Girlich Ch, Bollheimer LC. *Insulin-Therapie des Typ 1 Diabetes mellitus bei Erwachsenen*. *Arzneimitteltherapie* 2006 (im Druck).
119. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977–86.
120. Nathan DM, Cleary PA, Backlund JY, Genuth SM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005;353:2643–53.
- 120a. Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in Type II (non-insulin-dependent) diabetes mellitus? *Diabetologia* 2000;43:125–30.
121. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 2000;23:B21–9.
122. Ohkubo Y, Kishikawa H, Araki E, Miyata T, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995;28:103–17.
123. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837–53.
124. Schiel R, Müller UA. Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial). *Exp Clin Endocrinol Diabetes* 1999;107:506–11.
125. Mazze RS, Strock ES, Simonson GD, Bergenstal RM. Type 2 diabetes master decision path - insulin therapy. In: Mazze RS, Strock ES, Simonson GD, Bergenstal RM (Hrsg.). *Staged diabetes management - a systematic approach*. Chichester: Verlag John Wiley & Sons, 2004:122–36.
126. Henry RR, Gumbiner B, Ditzler T, Wallace P, et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-month outpatient trial. *Diabetes Care* 1993;16:21–31.
127. Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung Arzneimittel-Richtlinie/AMR vom 18.07.2006. http://www.g-ba.de/cms/upload/pdf/abs5/beschlusse/2006-07-18-AMR-Insulinanaloga_WZ.pdf. Internetdokument 2006.
128. IQWiG. Nutzenbewertung kurz wirksamer Insulinanaloge bei Patienten mit Typ-2-Diabetes-mellitus. <http://www.iqwig.de>. Internetdokument 2005.
129. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. *Clin Ther* 1997;19:62–72.
130. Ross SA, Zinman B, Campos RV, Strack T. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. *Clin Invest Med* 2001;24:292–8.
131. Altuntas Y, Ozen B, Ozturk B, Sengul A, et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. *Diabetes Obes Metab* 2003;5:371–8.
132. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycaemic control in patients with type 2 diabetes. *Diabetes Care* 2004;27:2363–8.
133. Plank J, Siebenhofer A, Berghold A, Jeitler K, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. *Arch Intern Med* 2005;165:1337–44.
134. Siebenhofer A, Plank J, Berghold A, Narath M, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. *Cochrane Database Syst Rev* 2004: Identifikationsnummer CD003287.
135. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. *Diabetes Care* 2006;29:435–49.
136. http://www.versorgungsleitlinien.de/themen/diabetes2/index_html.